Incorporating biomarkers such as programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB) can markedly improve the accuracy of predicting the effectiveness of combining stereotactic body radiotherapy (SBRT) with immunotherapy in treating non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.